Development and application of a CNS PBPK model that integrates CSF dynamics to optimize dosing regimens of

Related Experiment Video

Updated: May 28, 2026

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

Chaozhuang Shen1, Yi Zheng2, Bing Liu3

  • 1Department of Clinical Pharmacy, Institute of Clinical Pharmacology, Key Laboratory of Chemical Biology (Ministry of Education), NMPA Key Laboratory for Clinical Research and Evaluation of Innovative Drug, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, China; Department of Clinical Pharmacy and Pharmacy Administration, West China school of Pharmacy, Sichuan University, Chengdu, China.

International Journal of Antimicrobial Agents
|May 26, 2026
PubMed

Insights

This study developed a physiologically-based pharmacokinetic (PBPK) model to optimize antimicrobial dosing for pediatric meningitis. The model accurately predicts drug exposure, guiding effective treatment strategies for central nervous system infections.

Area of Science:

  • Pharmacokinetics and Pharmacodynamics
  • Central Nervous System (CNS) Physiology
  • Pediatric Infectious Diseases

Background:

  • Age-dependent cerebrospinal fluid (CSF) dynamics and disease-induced alterations complicate antimicrobial exposure assessment in pediatric meningitis.
  • Accurate quantification of drug concentrations in the CNS is crucial for effective treatment and minimizing toxicity.

Purpose of the Study:

  • To develop a CNS physiologically-based pharmacokinetic (PBPK) model for pediatric meningitis.
  • To characterize CNS drug exposure and inform optimized clinical dosing regimens.
  • To account for age-related physiological changes and disease effects.

Main Methods:

  • A CNS PBPK model was constructed, incorporating general physiological processes, disease effects, and developmental characteristics.
  • The model was applied to pediatric meningitis patients across various age subgroups.
  • Model validation was performed using literature and real-world data, achieving high prediction accuracy.

Main Results:

  • The PBPK model demonstrated high accuracy, with 98.7% of predictions within a 2-fold error margin.
  • Optimized vancomycin and meropenem dosing regimens were proposed based on age, MIC, and desired therapeutic targets (e.g., fT>MIC).
  • The model characterized meningitis-induced changes in blood-brain barrier permeability and route-dependent brain exposure.

Conclusions:

  • The developed CNS PBPK model provides a powerful in silico tool for optimizing antibacterial dosing in pediatric CNS infections.
  • This framework supports evidence-based clinical decision-making for improved patient outcomes.
  • The model aids in balancing antimicrobial efficacy with reduced toxicity risks.
Abstract

Keywords:
Antibacterial agentsCentral Nervous SystemModel informed precision dosingPaediatricsPhysiologically based pharmacokinetic

Related Concept Videos

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Pharmacodynamic Models: Overview01:27

Pharmacodynamic Models: Overview

Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Bacterial Meningitis II: Pathophysiology01:26

Bacterial Meningitis II: Pathophysiology

Bacterial meningitis typically begins when pathogens such as Neisseria meningitidis and Streptococcus pneumoniae colonize the nasopharynx and invade the bloodstream. This process is facilitated by bacterial virulence factors, such as polysaccharide capsules, which resist phagocytosis and complement-mediated killing. Less commonly, bacteria reach the central nervous system via contiguous spread from infections like otitis media or sinusitis, through congenital or acquired dural defects, or...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations01:15

Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations

Gentamicin, an aminoglycoside antibiotic, is commonly administered via intermittent intravenous infusion to treat severe infections. An intermittent one-hour infusion of gentamicin, administered at eight-hour intervals, allows for precise control of plasma drug concentrations, minimizing toxicity while ensuring therapeutic efficacy. Pharmacokinetic principles govern the dynamics of plasma concentrations and can be mathematically described using specific equations.The plasma drug concentration...